Sign in or Register   Sign in or Register
  |  

Mouse Anti-MEN1 (C-terminus) Recombinant Antibody (CBFYM-2063) (CBMAB-M2244-FY)

This product is mouse antibody that recognizes MEN1. The antibody CBFYM-2063 can be used for immunoassay techniques such as: IHC-P, IP, WB.
See all MEN1 antibodies

Summary

Host Animal
Mouse
Specificity
Human
Clone
CBFYM-2063
Antibody Isotype
IgG1, k
Application
IHC-P, IP, WB

Basic Information

Specificity
Human
Antibody Isotype
IgG1, k
Clonality
Monoclonal
Application Notes
The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format
Liquid
Buffer
TBS
Preservative
0.09% Sodium azide
Concentration
1 mg/mL
Storage
Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.
Epitope
C-terminus

Target

Full Name
MEN1
Introduction
This gene encodes menin, a putative tumor suppressor associated with a syndrome known as multiple endocrine neoplasia type 1. In vitro studies have shown menin is localized to the nucleus, possesses two functional nuclear localization signals, and inhibits transcriptional activation by JunD, however, the function of this protein is not known. Two messages have been detected on northern blots but the larger message has not been characterized. Alternative splicing results in multiple transcript variants.
Entrez Gene ID
4221
UniProt ID
O00255
Alternative Names
Menin 1; Menin; SCG2; Multiple Endocrine Neoplasia I; MEAI
Function
Essential component of a MLL/SET1 histone methyltransferase (HMT) complex, a complex that specifically methylates 'Lys-4' of histone H3 (H3K4). Functions as a transcriptional regulator. Binds to the TERT promoter and represses telomerase expression. Plays a role in TGFB1-mediated inhibition of cell-proliferation, possibly regulating SMAD3 transcriptional activity. Represses JUND-mediated transcriptional activation on AP1 sites, as well as that mediated by NFKB subunit RELA. Positively regulates HOXC8 and HOXC6 gene expression. May be involved in normal hematopoiesis through the activation of HOXA9 expression (By similarity).

May be involved in DNA repair.
Biological Process
Brain development Source: Ensembl
Cellular response to DNA damage stimulus Source: UniProtKB
Cellular response to glucose stimulus Source: Ensembl
Cellular response to peptide hormone stimulus Source: Ensembl
Chromatin organization Source: UniProtKB-KW
Decidualization Source: Ensembl
DNA repair Source: UniProtKB
Histone H3-K4 methylation Source: UniProtKB
MAPK cascade Source: UniProtKB
Mitotic cell cycle Source: Ensembl
Negative regulation of cell cycle Source: UniProtKB
Negative regulation of cell cycle G1/S phase transition Source: Ensembl
Negative regulation of cell population proliferation Source: UniProtKB
Negative regulation of cell-substrate adhesion Source: Ensembl
Negative regulation of cyclin-dependent protein serine/threonine kinase activity Source: UniProtKB
Negative regulation of DNA-binding transcription factor activity Source: UniProtKB
Negative regulation of epithelial cell proliferation Source: Ensembl
Negative regulation of JNK cascade Source: UniProtKB
Negative regulation of osteoblast differentiation Source: MGI
Negative regulation of protein phosphorylation Source: UniProtKB
Negative regulation of telomerase activity Source: UniProtKB
Negative regulation of transcription, DNA-templated Source: UniProtKB
Negative regulation of transcription by RNA polymerase II Source: UniProtKB
Osteoblast development Source: MGI
Positive regulation of protein binding Source: UniProtKB
Positive regulation of transcription by RNA polymerase II Source: UniProtKB
Positive regulation of transforming growth factor beta receptor signaling pathway Source: UniProtKB
Regulation of activin receptor signaling pathway Source: Ensembl
Regulation of transcription by RNA polymerase II Source: GO_Central
Regulation of type B pancreatic cell proliferation Source: Ensembl
Response to gamma radiation Source: UniProtKB
Response to transforming growth factor beta Source: Ensembl
Response to UV Source: UniProtKB
Type B pancreatic cell differentiation Source: Ensembl
Cellular Location
Nucleus
Note: Concentrated in nuclear body-like structures. Relocates to the nuclear matrix upon gamma irradiation.
Involvement in disease
Familial multiple endocrine neoplasia type I (MEN1):
Autosomal dominant disorder characterized by tumors of the parathyroid glands, gastro-intestinal endocrine tissue, the anterior pituitary and other tissues. Cutaneous lesions and nervous-tissue tumors can exist. Prognosis in MEN1 patients is related to hormonal hypersecretion by tumors, such as hypergastrinemia causing severe peptic ulcer disease (Zollinger-Ellison syndrome, ZES), primary hyperparathyroidism, and acute forms of hyperinsulinemia.
MEN1 inactivating mutations are responsible for hyperfunctioning of the parathyroid glands and subsequent primary hyperparathyroidism. Primary hyperparathyroidism can occur in isolation or in association with multiple endocrine neoplasia.

Perner, F., Stein, E. M., Wenge, D. V., Singh, S., Kim, J., Apazidis, A., ... & Cai, S. F. (2023). MEN1 mutations mediate clinical resistance to menin inhibition. Nature, 615(7954), 913-919.

Duan, S., Sheriff, S., Elvis-Offiah, U. B., Witten, B. L., Sawyer, T. W., Sundaresan, S., ... & Merchant, J. L. (2023). Clinically defined mutations in MEN1 alter its tumor-suppressive function through increased menin turnover. Cancer Research Communications, 3(7), 1318-1334.

Dreijerink, K. M., Ozyerli-Goknar, E., Koidl, S., van der Lelij, E. J., van den Heuvel, P., Kooijman, J. J., ... & Timmers, H. M. (2022). Multi-omics analyses of MEN1 missense mutations identify disruption of menin–MLL and menin–JunD interactions as critical requirements for molecular pathogenicity. Epigenetics & chromatin, 15(1), 29.

Welsch, C., Flügel, A. K., Rondot, S., Schulze, E., Sircar, I., Nußbaumer, J., & Bojunga, J. (2022). Distinct clinical phenotypes in a family with a novel truncating MEN1 frameshift mutation. BMC Endocrine Disorders, 22(1), 1-8.

Kooblall, K. G., Boon, H., Cranston, T., Stevenson, M., Pagnamenta, A. T., Rogers, A., ... & Thakker, R. V. (2021). Multiple endocrine neoplasia type 1 (MEN1) 5′ UTR deletion, in MEN1 family, decreases Menin expression. Journal of Bone and Mineral Research, 36(1), 100-109.

Qiu, H., Jin, B. M., Wang, Z. F., Xu, B., Zheng, Q. F., Zhang, L., ... & Jin, G. H. (2020). MEN1 deficiency leads to neuroendocrine differentiation of lung cancer and disrupts the DNA damage response. Nature Communications, 11(1), 1009.

Kamilaris, C. D., & Stratakis, C. A. (2019). Multiple endocrine neoplasia type 1 (MEN1): an update and the significance of early genetic and clinical diagnosis. Frontiers in endocrinology, 10, 339.

Ask a question We look forward to hearing from you.
0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Loading...
Have you used Mouse Anti-MEN1 (C-terminus) Recombinant Antibody (CBFYM-2063)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon $30 eGift Card
Submit a review
Loading...
For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Documents

Contact us

  • Tel: (USA)
  • (UK)
  • Fax:
  • Email:

Submit A Review

Go to
Compare